Acromegaly - Drug Pipeline Landscape, 2023

Acromegaly - Drug Pipeline Landscape, 2023

Acromegaly is a rare hormonal condition that results from an excess amount of growth hormone (GH) in the body. The extra amount of GH causes excess growth in the bones and soft tissues of the body. Children with the condition can grow to abnormal heights.

The most common cause of acromegaly is a tumor in your pituitary gland called a pituitary adenoma that causes pituitary gland to release excess growth hormone (GH). Pituitary adenomas (tumors) are almost always benign (noncancerous).

Acromegaly affects body's bones and tissues and causes them to grow in irregular ways. Symptoms include changes in face shape, including a more prominent jaw and/or forehead, increase in size of lips, nose and/or tongue, Excessive sweating or oily skin and deepening of voice.

IGF test and Oral glucose tolerance test are commonly suggested for the diagnosis of Acromegaly. Imaging tests like magnetic resonance imaging and computed tomography scan are used for diagnosis.

There are several treatment options for acromegaly. The most common treatments for acromegaly are surgery, medication and radiation therapy.

There are many companies active in development of Acromegaly Drugs such as  Camarus AB, Crinetics Pharmaceuticals Inc etc.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Acromegaly treatment such as Octreotide, Paltusotine, Cimdelirsen and others. Key players involved in the development of therapies to treat acromegaly are Camurus AB, Crinetics Pharmaceuticals Inc, Genevant Sciences Ltd, Ionis Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd and others. Two drugs are under late clinical-stage Phase III clinical trials and four drugs are in phase II and some other drugs are under preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Acromegaly - Drug Pipeline Landscape, 2023 report provides an overview of the Acromegaly pipeline drugs. This report covers detailed insights on Acromegaly drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acromegaly pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations, SEC filings, journals, conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage, molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development process such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Acromegaly - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Acromegaly
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Acromegaly - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical State Drugs- Phase III
5.1.1 Octreotide
5.1.2 Paltusotine
5.2 Clinical State Drugs-Phase II
5.2.1 Atesidorsen
5.2.2 Cimdelirsen
5.2.3 GT-02037
5.2.4 Somatropim
5.3 Clinical State Drugs- Phase I
5.3.1 Lanreotide Acetate
5.3.2 Octreotide
5.3.3 Octreotide
5.3.4 ONO-ST-468
5.3.5 ONO-5788
5.3.6 SomaDex
5.4 Clinical State Drugs - Preclinical
5.4.1 AZP-3813
5.4.2 GNV705
5.4.3 MOD-12014
5.4.4 Octreotide
5.5 Unknown Stage Drugs
5.5.1 FP-002
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Amolyt Pharma
9.2 Antisense Therapeutics
9.3 Aquestive Therapeutics Inc
9.4 ASCIL Biopharm
9.5 Camurus AB
9.6 Crinetics Pharmaceuticals Inc
9.7 Debiopharm International SA
9.8 DexTech Medical AB
9.9 Foresee Pharmaceuticals Co Ltd
9.10 Genevant Sciences Ltd
9.11 GlyTech Inc
9.12 Ionis Pharmaceuticals Inc
9.13 Ono Pharmaceutical Co Ltd
9.14 OPKO Health Inc
9.15 Rani Therapeutics LLC
9.16 Xeris Pharmaceuticals Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Acromegaly
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Octreotide/Camurus AB
Table 2.2 Clinical Trial Details – Paltusotine/ Crinetics Pharmaceuticals Inc
Table 2.3 Clinical Trial Details – Atesidorsen/ Antisense Therapeutics
Table 2.4 Clinical Trial Details – Cimdelirsen/Ionis Pharmaceuticals, Inc
Table 2.5 Clinical Trial Details – GT-02037/GlyTech Inc
Table 2.6 Clinical Trial Details – Somatropim/Xeris Pharmaceuticals Inc
Table 2.7 Clinical Trial Details – Lanreotide acetate/ASCIL Biopharm
Table 2.8 Clinical Trial Details – Octreotide/Debiopharm International SA
Table 2.9 Clinical Trial Details – Octreotide/Rani Therapeutics LLC
Table 2.10 Clinical Trial Details – ONO-5788/Ono Pharmaceutical Co Ltd
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Acromegaly, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Acromegaly, 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Acromegaly, 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Acromegaly, 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Acromegaly, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings